WeVote
Log In

Bill

Bill

AB 1320

California Affordable Drug Manufacturing Act of 2020: opioid antagonists.

2025-2026 Regular Session Introduced by Joe Patterson

AB 1320 establishes state-manufactured opioid antagonists to reduce drug costs and increase overdose-reversal medication access across California communities.

In committee: Set, first hearing. Failed passage. Reconsideration granted.
#californiaaffordabledrugmanufacturingactof2020 #opioidantagonists
0
WeVote Research Nonpartisan
Bill Summary · AB 1320

Legislative bill overview

AB 1320 proposes to establish a state-operated or state-supported program to manufacture opioid antagonists (such as naloxone/Narcan) in California, potentially at reduced costs. The bill aims to increase affordable access to these life-saving medications by circumventing traditional pharmaceutical supply chains and pricing mechanisms.

Why is this important

Opioid antagonists are critical overdose-reversal medications, yet high costs can limit accessibility in underserved communities and harm-reduction programs. State-level drug manufacturing could address medication shortages and pricing barriers while potentially serving as a model for other essential medications.

Potential points of contention

  • Manufacturing feasibility and cost: Questions about whether state manufacturing would actually be more cost-effective than existing generic options, and the startup/operational expenses involved
  • Federal regulatory compliance: State facilities would need FDA licensing and oversight; unclear how state operations would navigate federal pharmaceutical regulations
  • Market competition concerns: Pharmaceutical manufacturers may argue state competition unfairly disadvantages private industry or question the program's long-term viability and sustainability

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.